KLF4 suppresses anticancer effects of brusatol via transcriptional upregulating NCK2 expression in melanoma

Biochem Pharmacol. 2024 May:223:116197. doi: 10.1016/j.bcp.2024.116197. Epub 2024 Apr 6.

Abstract

Brusatol (Bru), a main extract from traditional Chinese medicine Brucea javanica, has been reported to exist antitumor effect in many tumors including melanoma. However, the underlying mechanism in its anti-melanoma effect still need further exploration. Here, we reported that the protein expression of KLF4 in melanoma cells were significantly downregulated in response to brusatol treatment. Overexpression of KLF4 suppressed brusatol-induced melanoma cell apoptosis; while knockdown of KLF4 enhanced antitumor effects of brusatol on melanoma cells not only in vitro but also in vivo. Further studies on the mechanism revealed that KLF4 bound to the promoter of NCK2 directly and facilitated NCK2 transcription, which suppressed the antitumor effect of brusatol on melanoma. Furthermore, our findings showed that miR-150-3p was dramatically upregulated under brusatol treatment which resulted in the downregulation of KLF4. Our results suggested that the miR-150-3p/KLF4/NCK2 axis might play an important role in the antitumour effects of brusatol in melanoma.

Keywords: KLF4; Melanoma; NCK2.

MeSH terms

  • Adaptor Proteins, Signal Transducing / genetics
  • Adaptor Proteins, Signal Transducing / metabolism
  • Apoptosis
  • Humans
  • Melanoma* / drug therapy
  • Melanoma* / genetics
  • Melanoma* / metabolism
  • MicroRNAs* / genetics
  • MicroRNAs* / pharmacology
  • Oncogene Proteins / metabolism
  • Quassins* / pharmacology

Substances

  • brusatol
  • Quassins
  • MicroRNAs
  • NCK2 protein, human
  • Oncogene Proteins
  • Adaptor Proteins, Signal Transducing